This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Quintessence Biosciences, Inc.
Drug Names(s): QBI-139
Description: QBI-139 is variant of a human ribonuclease (RNase)that has diminished binding to its natural intracellular inhibitor. QBI-139 retains 95% sequence identity to a naturally occurring RNase.
The drug is based on the company's EVade Ribonuclease technology which generates analogs of the human pancreatic ribonuclease 1.
Additional information available to subscribers only: